Not medical advice. Talk to your provider before using any peptide. Full disclaimer
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)
Beginner tier: 2 mg, daily · 10w on / 4w off · community consensus
Also known as: KLOW Peptide, KLOW Protocol, KLOW Stack
Four research peptides in a single 80mg vial, each targeting a different repair pathway. The KLOW Blend combines GHK-Cu, BPC-157, TB-500, and KPV into a fixed-ratio formulation designed for tissue recovery, gut support, and skin integrity during aggressive fat loss. Zero clinical trials exist for the combination itself; all four components remain preclinical for injectable use in humans. That said, the individual ingredient data is real. GHK-Cu shifts the activity of at least 4,000 human genes in cell-line data (PMID 26236730 (opens in a new tab)). For BPC-157, 35 of the 36 studies in a 2025 orthopaedic review were preclinical (PMID 40756949 (opens in a new tab)). Users pair KLOW with GLP-1 agonists to offset GI side effects and preserve skin elasticity during rapid weight loss.
What Is KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)?
Does stacking four preclinical peptides in one vial actually make sense? The KLOW Blend (also called the KLOW Protocol) puts GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg) together in a fixed 5:1:1:1 ratio. It evolved from the three-peptide GLOW stack. The addition of KPV brought anti-inflammatory gut protection into the mix.
Each component works through a separate mechanism. GHK-Cu is a copper-binding tripeptide first isolated by Loren Pickart in 1973. His group's analysis of public gene data from human cell lines found it shifts the activity of at least 4,000 genes (PMID 26236730 (opens in a new tab)). In skin cell cultures it increased collagen and elastin production [1]. BPC-157 is a 15-amino-acid gastric juice fragment. Predrag Sikiric's group in Zagreb appears on 175 of its 233 PubMed records (October 2026), including a rat study of faster intestinal anastomosis healing [2]. A Taiwanese lab tied its tendon effect to FAK-paxillin signaling in rat tendon fibroblasts [5]. TB-500, a synthetic fragment of thymosin beta-4, promotes actin polymerization and cell migration. Goldstein's original work showed it increased keratinocyte migration 2- to 3-fold at concentrations as low as 10pg [3]. KPV enters intestinal epithelial cells via the PepT1 transporter and suppresses NF-kB inflammatory signaling at nanomolar concentrations (Dalmasso et al.)[4].
The typical community protocol runs 2000mcg total blend per day for 10 weeks, followed by 4 weeks off. Most of the interest comes from the GLP-1 companion use case. Users on semaglutide or tirzepatide report that KLOW reduces nausea and supports skin tightening during rapid weight loss. That framing is entirely anecdotal. No clinical endpoint data supports it.
The FDA classified BPC-157 and GHK-Cu as Category 2 bulk drug substances in 2023-2024, restricting compounding pharmacy access. Both BPC-157 and TB-500 are WADA-prohibited. Research-grade prices run $65 to $380 per vial, with most landing near $100 to $135.
How KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Works
The four peptides in KLOW operate through distinct signaling cascades that happen to converge on tissue repair, inflammation control, and extracellular matrix remodeling.
GHK-Cu delivers bioavailable copper into dermal and connective tissue. It activates fibroblast proliferation and upregulates genes for collagen I, collagen III, elastin, and glycosaminoglycans. Pickart's work [1] identified at least 4,000 human genes that GHK-Cu raises or lowers, including antioxidant enzymes like superoxide dismutase. The copper chelation is not optional; free GHK tripeptide without the Cu2+ complex lacks most biological activity.
BPC-157 interacts with the nitric oxide system and upregulates growth hormone receptor expression. Chang Gung University researchers linked it to angiogenesis through VEGFR2-Akt-eNOS signaling in rats and endothelial cells [10]. An earlier study there tied faster tendon outgrowth to FAK-paxillin signaling in rat tendon fibroblasts [5]. It also protects endothelial function and modulates dopamine and serotonin systems.
TB-500 sequesters G-actin monomers, preventing premature polymerization. This allows orderly cytoskeletal reorganization at wound sites. Goldstein's group showed thymosin beta-4 increased keratinocyte migration 2- to 3-fold at 10pg concentrations [3]. A first-in-human Phase I study of IV recombinant thymosin beta-4 in healthy Chinese volunteers (54 single-dose, 30 multiple-dose) established basic tolerability [6].
KPV enters cells via the PepT1 transporter expressed on intestinal epithelial and immune cells. Once inside, it stabilizes IkB-alpha, preventing NF-kB nuclear translocation. Dalmasso et al. [4] showed oral KPV reduced colitis incidence in DSS and TNBS animal models. A separate group confirmed KPV's anti-inflammatory activity in human bronchial epithelial cells [7].
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Benefits
- KLOW Blend benefits center on tissue recovery, gut protection, and body recomposition support during aggressive fat loss phases.
- Reduces systemic inflammation through NF-kB pathway suppression. KPV enters intestinal epithelial cells via PepT1 and blocks pro-inflammatory cytokine production at nanomolar concentrations (Dalmasso et al.)[4].
- Supports gut mucosal healing in rats; use during GLP-1 therapy rests on user reports. BPC-157's gut protective effects come mostly from rat studies by Sikiric's Zagreb group [2][8]. Users on semaglutide and tirzepatide consistently report reduced nausea and bloating when adding KLOW.
- Supports skin elasticity and collagen production during rapid weight loss. GHK-Cu upregulates collagen I, collagen III, and elastin genes (Pickart)[1]. Community reports describe visible skin tightening by weeks 5 to 7 of a cycle.
- Promotes tendon and ligament repair. BPC-157 drives tendon outgrowth through FAK-paxillin signaling [5]; TB-500 promotes cell migration via actin polymerization [3]. Together they cover two separate tissue repair mechanisms.
- Preserves connective tissue integrity during caloric restriction. Users running 500+ calorie deficits report less joint stiffness and fewer soft tissue complaints when cycling KLOW at beginner dose.
- Offers single-vial convenience over sourcing four separate peptides. One reconstitution, one daily injection, four active components.
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV): Science vs Community Consensus
No clinical data exists for the four-peptide KLOW combination.
Read the evidence (key study, limitations)
Individual component evidence is preclinical (BPC-157, TB-500, GHK-Cu, KPV each have animal model data). First human BPC-157 IV safety pilot (Lee & Burgess 2025, n=2)[9] showed tolerability up to 20mg IV; no efficacy claims possible from n=2.
PMC12313605 (Vasireddi et al. 2025, systematic review BPC-157 orthopaedics, 35 preclinical + 1 clinical); PMID 40131143 (Lee & Burgess 2025, BPC-157 IV human pilot, n=2)
Zero combination studies. All four components are preclinical-only for injection use in humans. FDA listed BPC-157 and GHK-Cu as Category 2 bulk drug substances (compounding ban, 2023-2024). TB-500 daily micro-dose format has no precedent: standard protocol is 2×/week bolus 2–5mg.
Emerging community stack with anecdotal reports of improved skin elasticity, reduced GI symptoms on GLP-1 agonists, and faster soft-tissue recovery.
Read the reports (what users report 4, common issues 5)
Dosing is inconsistent across sources: community consensus (200–500mcg/day total blend, per community reports) diverges significantly from commercially marketed tiers (2000–4800mcg/day).
- Skin elasticity improvement during rapid weight loss (GHK-Cu collagen pathway)
- GI comfort and reduced nausea when pairing with GLP-1 agonists (KPV gut inflammation)
- Soft tissue and joint recovery during caloric restriction (BPC-157 + TB-500)
- All-in-one convenience vs. sourcing and dosing 4 separate peptides
- Expensive per-vial cost; burns through vials quickly at moderate/aggressive tiers
- No standardized dosing: wide community disagreement
- GHK-Cu copper skin flushing and redness at higher dose tiers
- TB-500 may be functionally underdosed in daily micro-dose format vs. standard bolus
- GLP-1 companion framing widely repeated but clinically unsupported
Individual components (BPC-157, GHK-Cu, KPV, TB-500) each have preclinical rationale supporting their combined use for tissue repair and inflammation. However, no combination study exists, the community-adopted GLP-1 companion framing lacks clinical evidence, and the commercially marketed dose tiers (2000–4800mcg/day) conflict with lower community estimates (200–500mcg/day). TB-500 daily micro-dosing is structurally inconsistent with its established 2×/week bolus protocol.
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Dosage Guide
For the pre-blended 80 mg vial (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg). Separate vials are covered under the table.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2 mg | DailyTrack |
| Moderate | 4 mgAbove the ceiling stated by both consensus lines on this page (2,000 mcg per day total). Delivers 2,500 mcg GHK-Cu, above the 1 to 2 mg per day community range. | DailyTrack |
| Aggressive | 4.8 mgAbove the ceiling stated by both consensus lines on this page. Delivers 3,000 mcg GHK-Cu, the top of the injectable range on the GHK-Cu page. It also delivers 600 mcg each of BPC-157 and KPV, above the 500 mcg per day top of the community range this page quotes for both. Do not exceed without prescriber oversight. | DailyTrack |
Reconstitution math for the 80mg vial: add 3mL bacteriostatic water to get 26.7mg/mL. At that concentration, 7.5 units on a 100-unit insulin syringe delivers 2000mcg (the beginner dose), 15 units delivers 4000mcg, and 18 units delivers 4800mcg. Going with 4mL instead gives you 20mg/mL with slightly larger but easier-to-measure draw volumes, but then every unit figure on this page has to be recalculated. All of them assume 3mL.
Swirl the vial gently after adding bac water. Don't shake it. Peptides aren't cocktails.
The blend ratio is fixed at 5:1:1:1 (GHK-Cu : BPC-157 : TB-500 : KPV). At beginner dose (2000mcg/day) you're getting GHK-Cu 1250mcg, BPC-157 250mcg, TB-500 250mcg, and KPV 250mcg. That BPC-157 number is within its typical standalone range. The TB-500 number (250mcg daily, or ~1.75mg per week) is structurally different from the standard TB-500 protocol (2 to 5mg bolus twice per week). Whether daily low-dose TB-500 equals bolus dosing is unknown.
One vial at beginner dose lasts about 40 days. At moderate (4000mcg/day) you'll burn through it in roughly 20 days.
Pin once daily, preferably in the evening. Rotate between at least four injection sites (left/right abdomen, left/right outer thigh).
- GHK-Cu: 3,000 mcg per day. Top of the injectable range on the GHK-Cu page (0.5 to 3 mg per day, community). No human dose-finding trial exists for injectable GHK-Cu.
- BPC-157: 500 mcg per day. Top of the community subcutaneous range on the BPC-157 page (250 to 500 mcg per day), the same range this page quotes for separate vials. That page also carries an aggressive tier of 500 mcg twice daily, so the two figures disagree. The lower one is used here because it is the figure this page already gives readers.
- KPV: 500 mcg per day. Top of the community subcutaneous range on the KPV page (200 to 500 mcg per day), the same range this page quotes for separate vials. The KPV page also carries an aggressive tier of 1,000 mcg per day extrapolated from mouse models. The lower community figure is used here.
Blend ratios are not standardized across products. Confirm the milligram breakdown on your COA before dosing. If your ratio differs, the component split above does not apply.
Which product do you have?
This blend is run in more than one way. The dosing table above describes the pre-blended 80 mg vial only.
The ratio is fixed at manufacture. You cannot move one component without moving all four. Raising the blend dose raises GHK-Cu with it, and GHK-Cu is the limiting component.
Community cycles run 10 weeks on and 4 weeks off, with weeks 1 to 4 held at the beginner dose. No trial supports this schedule.
- GHK-Cu: 1 to 2 mg per day (community). Own page carries the full tier set.
- BPC-157: 250 to 500 mcg per day (community). Own page carries the full tier set.
- TB-500: 2 mg twice weekly (community). The twice-weekly schedule is the reason many users choose separate vials; a pre-blended vial forces a daily micro-dose instead.
- KPV: 200 to 500 mcg per day (community). The published KPV work is oral dosing in mice (PMID 18061177); no human injectable dose has been established.
With separate vials you set each dose yourself and the 5:1:1:1 ratio no longer binds. Each range above comes from the component page on this site, and none of them has trial support for use in this combination. Pick with a prescriber.
Community cycles run 10 weeks on and 4 weeks off. Separate vials let TB-500 keep its twice-weekly schedule.
GHK-Cu sets the tier (1 to 2 mg per day, subcutaneous). Community consensus. No human trial establishes an injectable GHK-Cu dose at any level.
GHK-Cu is 50 mg of the 80 mg vial, so it is 62.5 percent of every draw. The beginner tier of 2,000 mcg delivers 1,250 mcg GHK-Cu with 250 mcg each of BPC-157, TB-500, and KPV. Moderate (4,000 mcg) delivers 2,500 mcg GHK-Cu. Aggressive (4,800 mcg) delivers 3,000 mcg GHK-Cu, the top of the injectable range on the GHK-Cu page.
Cycling Protocol
Run daily injections for 10 weeks. Weeks 1 to 4 are the loading phase at the beginner dose, so the earliest a dose increase makes sense is week 5, and only if week 4 went well. Take 4 weeks off before repeating. Most users run 2 to 3 cycles per year. When pairing with GLP-1 agonists, start KLOW 1 to 2 weeks before the GLP-1 to establish a baseline of gut and tissue support.
KLOW cycling is driven primarily by safety monitoring (unstudied four-component combination; copper accumulation risk from GHK-Cu with extended use) and extrapolation from individual component protocols (BPC-157 and TB-500 are typically run in 8–12 week cycles with breaks). No receptor desensitization data exists for this combination, and no hormonal axis is suppressed.
- Diminishing tissue repair response in weeks 9–10 signals end of productive cycle window
- Copper-related symptoms (persistent flushing, metallic taste) indicate immediate cycle pause
- GI distress not attributable to GLP-1 co-therapy: reassess at 4-week mark before advancing dose
Or use the universal Peptide Calculator for any peptide.
One page: what is in the vial, the dose each tier delivers per component, syringe units, cycling, and where every number comes from.
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Protocols by Goal
Expected: Reduced joint discomfort and soft tissue soreness by weeks 3–4; skin hydration and elasticity improvement by weeks 5–7; peak healing support by weeks 8–10
Monitor: Baseline copper levels recommended before starting. Monitor for skin flushing (GHK-Cu copper load). Track injection site reactions.
How to Inject KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)
- 1Remove the flip-top cap from the 80mg lyophilized KLOW vial
Wipe the rubber stopper with an alcohol swab.
- 2Draw 3mL of bacteriostatic water into a syringe
Inject it slowly down the inside wall of the vial. Do not spray directly onto the peptide cake.
- 3Swirl gently until fully dissolved
Do not shake. The solution should be clear with no visible particles.
- 4Step 4
Using a 29 to 31 gauge insulin syringe (100-unit markings), draw to the 7.5-unit line for a 2000mcg beginner dose. For moderate dosing (4000mcg), draw to 15 units. For aggressive (4800mcg), draw to 18 units. Every unit figure on this page assumes the 3mL reconstitution from step 2. At 4mL the concentration is 20mg/mL and all of these numbers change.
- 5Step 5
Pinch a fold of skin on the abdomen (2 inches from the navel) or outer thigh. Insert the needle at a 45-degree angle.
- 6Inject slowly
Hold for 5 seconds before withdrawing the needle. Apply light pressure with an alcohol swab if needed.
- 7Step 7
Administer once daily, preferably in the evening to align with overnight tissue repair cycles. Rotate injection sites each day. Keep a brief log so you don't hit the same spot twice in a row.
- 8Step 8
Store the reconstituted vial upright in the refrigerator at 2 to 8 degrees Celsius. Use within 4 weeks of reconstitution.
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Stacking Protocols
Works With
Most discussed KLOW pairing. KPV targets GLP-1-induced gut inflammation; BPC-157 supports mucosal healing; GHK-Cu addresses skin elasticity during rapid weight loss.
Start KLOW 1–2 weeks before semaglutide initiation. Inject separately, different sites.
Same rationale as semaglutide. Dual GIP/GLP-1 agonism may cause more GI distress: KPV anti-inflammatory component potentially more relevant.
Post-surgical or severe injury recovery: additional standalone BPC-157 bolus to supplement the fixed-ratio KLOW blend component (which delivers only 250–600mcg/day BPC-157). Allows therapeutic BPC-157 dose without replacing the full blend.
Predecessor stack: KLOW is GLOW + KPV. Users switch from GLOW to KLOW when GI inflammation or gut support is a priority. Not typically run simultaneously.
Avoid
GHK-Cu delivers bioavailable copper. Combined use risks copper overload, particularly at moderate/aggressive KLOW tiers (GHK-Cu 2500–3000mcg/day).
Do not combineCompetitive inhibition at copper transport sites reduces GHK-Cu uptake and effectiveness.
BPC-157 and GHK-Cu both promote angiogenesis; combined use may affect clotting dynamics.
KPV and TB-500 modulate immune pathways; may reduce or unpredictably amplify immunosuppressive effects.
Estimated Cost
Pricing updated 2026-04-09
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Side Effects
Three of the four KLOW components promote angiogenesis and growth factor signaling. Anyone with a current cancer diagnosis or cancer history should not use this blend. That is the most serious safety concern, and it is not negotiable.
No human clinical trial data exists for the four-peptide combination. Every side effect profile below is extrapolated from research on individual components.
Injection site reactions are the most frequently reported issue. Redness, mild swelling, or itching at the injection site typically resolves within an hour. This is common across all subcutaneous peptide injections and not specific to KLOW.
GHK-Cu's copper content can cause transient skin flushing. Some users describe a warm, reddish tint across the face or chest lasting 20 to 40 minutes after injection. At higher dose tiers (moderate delivers 2500mcg GHK-Cu per day; aggressive delivers 3000mcg), copper accumulation over a 10-week cycle becomes a legitimate concern. Serum copper and ceruloplasmin monitoring is recommended at baseline and mid-cycle for anyone running above the beginner tier.
BPC-157 may cause mild nausea, dizziness, or headache. These effects are more common at higher doses and when injecting on an empty stomach. The first-in-human IV safety pilot by Lee and Burgess (n=2)[9] showed tolerability up to 20mg IV. That sample size tells you almost nothing about population-level side effects.
TB-500 has been associated with temporary lethargy and mild headache during loading phases. Community reports suggest this fades by week 2 to 3.
KPV side effects are rare in published literature.
Some users experience increased fatigue during the first week. A smaller number report mild GI discomfort, bloating, or changes in bowel frequency. When paired with a GLP-1 agonist, additive GI effects in the first two weeks of overlap deserve attention.
Pregnancy and breastfeeding are absolute contraindications. Wilson's disease or copper metabolism disorders rule out KLOW due to the GHK-Cu component. Active autoimmune conditions in flare warrant caution because TB-500 and BPC-157 modulate immune signaling in unpredictable ways.
Long-term safety of this four-peptide combination is unknown. Stop the cycle and consult a physician if you experience persistent copper-related symptoms (metallic taste, facial flushing that does not resolve), unusual bleeding or bruising, or any signs of allergic reaction.
Common Issues & Solutions
Copper skin flushing or redness (GHK-Cu): reduce to or maintain beginner dose (2000mcg/day); ensure no concurrent copper supplementation; if persistent, pause cycle and recheck serum copper.
Nausea or dizziness after injection (BPC-157 component): switch to evening dosing after a light meal; confirm dose is at beginner tier (250mcg BPC-157 equivalent at 2000mcg total blend).
Injection site soreness or persistent redness: rotate sites more aggressively (minimum 4 sites: L/R abdomen, L/R thigh); inspect reconstitution for particulates; ensure 29–31 gauge needle and proper SC technique.
TB-500 efficacy concern from the blend: at 2000mcg/day total the blend delivers ~250mcg TB-500 daily (~1.75mg/week) vs. standard 2×/week bolus of 2–5mg. If TB-500 tissue repair is the primary goal, consider standalone TB-500 on its bolus protocol instead of relying on the KLOW blend ratio.
Vial consumption rate: at beginner dose (2000mcg/day, 0.075mL/injection) one 80mg vial at 3mL lasts ~40 days. At moderate (4000mcg/day, 0.15mL): ~20 days.
Ask AI about this page
Ask AI for a second opinion on KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) dosing and side effects
Contraindications
- Pregnancy or breastfeeding
- Active cancer or history of cancer (GHK-Cu promotes angiogenesis; BPC-157 upregulates growth factors: both may support tumor growth)
- Wilson's disease or copper metabolism disorders (GHK-Cu delivers bioavailable copper)
- Active autoimmune conditions in flare (TB-500 and BPC-157 modulate immune signaling)
- Known allergy to copper or any component peptide
- Children under 18 years of age
Drug Interactions
- Copper supplements: risk of copper overload when combined with GHK-Cu
- Anticoagulants and blood thinners: BPC-157 and GHK-Cu promote angiogenesis and may affect clotting dynamics
- NSAIDs: BPC-157 interacts with the nitric oxide and prostaglandin systems; combined use may alter anti-inflammatory balance
- Immunosuppressants: KPV and TB-500 modulate immune pathways; may reduce or amplify immunosuppressive effects
- GLP-1 receptor agonists: generally used together intentionally but monitor for additive GI effects during the first 2 weeks
- Corticosteroids: TB-500 and BPC-157 may partially counteract steroid-induced tissue atrophy, but combined use is unstudied
- High-dose zinc supplements (>50mg/day): competitive inhibition at copper transport sites can reduce GHK-Cu uptake
- Anticoagulants / blood thinners (warfarin, heparin)
Product Quality
Multi-component research blend with no FDA oversight. BPC-157 and GHK-Cu are classified as FDA Category 2 bulk drug substances (compounding ban, 2023–2024). Wide market price range ($65–$380/vial) reflects inconsistent quality standards. No combination stability data published: peptide degradation rates within a four-component lyophilized blend are unknown. WADA prohibits BPC-157 and TB-500 (risk for tested athletes).
- Third-party CoA (certificate of analysis) benchmark for each batch: HPLC purity ≥98% and mass spectrometry confirmation of all four components.
- Treat a single-vial price below $65 as a quality flag: that is the rough cost-of-goods floor for quality multi-peptide synthesis. Bulk 10-vial kits legitimately land near $46 per vial, so compare like for like before reading price as a signal.
- Verify GHK-Cu is the copper-complexed form (GHK-Cu²⁺) not free GHK tripeptide: copper chelation is essential for activity.
- Legal status of compounded KLOW from pharmacies is uncertain post-FDA Category 2 classification.
- WADA-tested athletes: both BPC-157 and TB-500 are prohibited under S2 (Peptide Hormones, Growth Factors, Related Substances).
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Serum copper and ceruloplasmin | Baseline before starting; mid-cycle at week 5 if running moderate/aggressive tiers | Serum copper 70–140 mcg/dL; ceruloplasmin 20–35 mg/dL |
| Liver function panel (ALT, AST, ALP, bilirubin) | Baseline; at 6 weeks if any GI symptoms develop | Within institutional reference range |
| CBC with differential | Baseline; repeat if unusual bleeding, bruising, or infection signs occur | Not listed |
| Cancer screening (age-appropriate, per clinical guidelines) | Before initiating any cycle; confirm no active malignancy or recent history | Not listed |
GHK-Cu delivers bioavailable copper; at moderate tier (2500mcg GHK-Cu/day) or aggressive tier (3000mcg/day) copper accumulation is a risk over 10 weeks
No combination hepatotoxicity data exists; general safety monitoring for unstudied four-component blend
Triple pro-angiogenic combination (BPC-157 + TB-500 + GHK-Cu): monitor hematologic impact; BPC-157 interacts with clotting dynamics
Three of four components promote angiogenesis and growth factor signaling: absolute contraindication in active or historical cancer diagnosis
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Before and After
Subtle improvements in energy and recovery. Some users notice reduced joint stiffness and improved sleep quality. Gut comfort may improve, especially if pairing with a GLP-1 agonist. This is the initial assessment period: stay at the beginner dose.
Anti-inflammatory effects become noticeable. Reduced bloating and improved digestion. Minor soft tissue aches begin to resolve. Skin hydration starts to improve as GHK-Cu collagen pathways activate.
Peak healing response. Tendon and ligament repair accelerates. Skin elasticity visibly improves, particularly in areas affected by weight loss. Systemic inflammation markers (if tracked via bloodwork) may show measurable decline.
Full benefits reached. Skin firmness and tone at their best for the cycle. Gut lining integrity well-supported. Users on GLP-1 therapy often report fewer GI side effects by this point. Evaluate results and prepare for the off-cycle.
Four-week break. BPC-157 and TB-500 healing effects persist as tissue remodeling continues. Collagen benefits from GHK-Cu have a slow turnover and remain visible. Reassess before starting another cycle.
What to Expect
Week 1 to 2 (Tolerance Assessment). Component absorption kicks in quickly. GHK-Cu activates fibroblast signaling within hours of injection; BPC-157 and KPV reach tissue concentrations within days based on animal PK data. Community reports describe subtle energy improvements and reduced joint stiffness. Users on GLP-1 agonists may notice early gut comfort improvements. Most people won't see dramatic changes yet. This window is about confirming you tolerate the blend at beginner dose (2000mcg/day). Common side effects include injection site redness and itching (usually gone within an hour), copper skin flushing in sensitive individuals, and mild nausea if injecting on an empty stomach.
Week 3 to 4 (Anti-Inflammatory Onset). KPV's NF-kB suppression starts producing measurable anti-inflammatory effects in animal IBD models by this point. GHK-Cu collagen gene upregulation continues building from week 1. Users report reduced bloating, improved digestion, and fading joint stiffness. Early skin hydration improvement shows up. The transient fatigue some people feel in week 1 generally resolves by now.
Week 5 to 7 (Peak Healing Response). This is the window where GHK-Cu-mediated collagen and elastin synthesis hits its stride, based on gene expression timelines from Pickart's research. BPC-157 angiogenic and tendon outgrowth effects reach peak activity in animal models. Community feedback points to visible skin elasticity gains, especially in areas with rapid fat loss. Tendon and ligament soreness fades. GLP-1 users commonly report that GI side effects have dropped off considerably.
Week 8 to 10 (Full Cycle Benefit). Tissue remodeling continues but you've hit the plateau. No human data exists for this time window specifically. Community reports indicate skin firmness and tone are at their best. Gut lining support appears well-established subjectively. This is the evaluation period before stepping into the off-cycle.
Week 11 to 14 (Off-Cycle Retention). Collagen driven by GHK-Cu has slow biological turnover, so those benefits persist beyond the last dose. BPC-157 and TB-500 tissue remodeling continues for weeks post-cycle based on animal data. Most users report retaining their gains through the four-week break. Reassess results at the end of week 14 before deciding on the next cycle.
Detailed Timeline: Science vs Community
Component absorption begins. GHK-Cu activates fibroblast signaling within hours; BPC-157 and KPV reach relevant tissue concentrations within days (animal model PK data only).
Subtle energy improvement and reduced joint stiffness reported. GI comfort may improve in GLP-1 users. Most users report little change: this is the assessment window.
KPV NF-kB suppression reduces measurable inflammatory markers in IBD animal models by 2–3 weeks. GHK-Cu collagen gene upregulation is sustained from week 1.
Reduced bloating and improved digestion noted. Minor soft tissue aches and joint stiffness diminishing. Early skin hydration improvement reported.
Maximum GHK-Cu-mediated collagen and elastin synthesis (based on gene expression timelines in Pickart data). BPC-157 angiogenic and tendon outgrowth effects peak in this window in animal models.
Visible skin elasticity improvement, particularly in areas with rapid fat loss. Tendon/ligament soreness resolving. GLP-1 GI side effects reported as markedly reduced.
Tissue remodeling plateau continues; no human data for this time window.
Skin firmness and tone at best point in cycle. Gut lining appears well-supported subjectively. Users evaluate results before off-cycle.
GHK-Cu-driven collagen has slow biological turnover; benefits persist beyond last dose. BPC-157 and TB-500 tissue remodeling continues for weeks post-cycle (animal data).
Most gains reported as retained through off-cycle. Reassess at end of 4 weeks before deciding on next cycle.
Pharmacokinetics
Source: Weighted estimate across four components. BPC-157 has the shortest plasma half-life (15.2 min after a single IV dose in rats, He et al. 2022, PMID 36588717), followed by KPV (~1-2h), GHK-Cu (~2-4h), and TB-500 (~2-3h). The dominant component by mass is GHK-Cu (62.5% of the blend), which anchors the effective duration. No unified PK data exists for the combined four-peptide formulation.
Molecular Profile
Is KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Legal?
KLOW Blend components carry mixed regulatory status. BPC-157 and GHK-Cu were classified as FDA Category 2 bulk drug substances in 2023 to 2024. This restricts their use in compounding pharmacy preparations, though enforcement and interpretation vary. TB-500 and KPV remain unscheduled but are not FDA-approved for any indication.
All four components are classified as research chemicals, not approved drugs. KLOW vials are sold for "research use only" and not for human consumption.
Both BPC-157 and TB-500 are prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Any athlete subject to anti-doping testing must avoid this blend entirely.
Compounding pharmacy availability for KLOW-type blends is legally uncertain given the Category 2 classifications. The research chemical market remains the primary access route.
This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any peptide product.
Who Should Consider KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)
- Individuals on GLP-1 agonists seeking gut protection and tissue support
- People in active weight loss phases wanting to preserve skin and connective tissue
- Athletes recovering from injuries while maintaining caloric deficits
- Adults with chronic low-grade inflammation affecting body composition
- Post-surgical patients needing accelerated tissue repair
- Those experiencing GI side effects from weight loss medications
Related Peptides
What Changed for KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)
Peptide Schedule Research TeamReviewed Apr 7, 202618 Citations
References
- [1]Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease heals ileoileal anastomosis in the rat (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Thymosin beta4 accelerates wound healing (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]First-in-human phase I study of recombinant human thymosin beta-4 in healthy Chinese volunteers (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Sikiric et al., Curr Pharm Des 2011) (opens in a new tab)PubMed (opens in a new tab)Review
- [9]Safety of intravenous infusion of BPC157 in humans: a pilot study (opens in a new tab)(n=2)PubMed (opens in a new tab)PubMed
- [10]Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health (Pickart et al., Oxid Med Cell Longev 2012) (opens in a new tab)PubMed 22666519PubMed
- The regenerative peptide thymosin beta-4 accelerates the rate of dermal healing in preclinical animal models and in patients (opens in a new tab)PubMed 23050815PubMed
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in mucosal inflammation (opens in a new tab)PubMed 18092346PubMed
- Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs (He et al., Front Pharmacol 2022) (opens in a new tab)PubMed 36588717PubMed
- GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration (Biomed Res Int 2015) (opens in a new tab)PubMed 26236730PubMed
- Thymosin beta4 and cardiac repair (opens in a new tab)PubMed 20536454PubMed
- Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis (Mol Ther 2017) (opens in a new tab)PubMed 28143741PubMed
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi et al., HSS J 2025) (opens in a new tab)PubMed 40756949Review
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)?
Emerging. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Low. Community mentions on Reddit: Low: lighter than GLOW stack.
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.